Phoenix Clinical Research LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$438,781	585
2023	Research	$5,659	4
2022	Research	$34,761	14
2021	Research	$47,860	17
2020	Research	$223,103	31
2019	Research	$92,910	18

Breakdown

Who paid Research payments · program years 2019–2025

Regeneron Pharmaceuticals, Inc. $438,781 585 payments
Janssen Research & Development, LLC $313,987 45 payments
Zimmer Biomet Holdings, Inc. $39,030 20 payments
Takeda Pharmaceuticals U.S.A., Inc. $25,396 13 payments
Endo Pharmaceuticals Inc. $14,525 3 payments
Pfizer Inc. $10,855 1 payment
Moderna TX, Inc. $500 2 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Multicenter, Randomized, Open-Label, Sponsor-Blinded, Study to Evaluate REGN7508, A Factor XI Monoclonal Antibody, Versus Apixaban and Enoxaparin for Prophylaxis of Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-APEX) $438,781 585 payments
A Randomized, Open-Label, Study Drug-Dose Blind, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-70033093 (BMS-986177), an Oral Factor XIa Inhibitor, Versus Subcutaneous Enoxaparin in Subjects Undergoing Elective Total Knee Replacement Surgery $275,838 33 payments
A Randomized Open Label Study Drug Dose Blind Multi Center Study to Evaluate the Efficacy and Safety of JNJ70033093 BMS986177 an Oral Factor XIa Inhibitor Versus Subcutaneous Enoxaparin in Subjects Undergoing Elective Total Knee Replacement Surgery $27,361 8 payments
A Randomized Double-Blind, Double-Dummy, Proof of Concept Phase 2 Study to Evaluate the Efficacy and Safety of Tak-951 Versus Ondansetron in the Prophylaxis of Postoperative Nausea and Vomiting in High-Risk Subjects $25,396 13 payments
Berkowitz, Richard, 04-500, TM Stem CSI 90-202 $12,850 4 payments
Berkowitz, Richard, 04-500, TM Stem CSI 90-202 $11,400 6 payments
A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study of the Longterm Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee $10,855 1 payment
A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design Dose-Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery $7,500 2 payments
Hip Registry $5,050 1 payment
CME2016-105H, Trilogy Survey $4,560 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.